Having More Cannabis Stores Linked to Fewer Opioid Deaths In The U.S.

by DailyHealthPost Editorial

The findings may have implications for tackling opioid misuse. Access to legal cannabis stores is associated with a reduction in opioid related deaths in the United States, particularly those linked to synthetic opioids such as fentanyl, finds a new study.

Opioids are ‘morphine-type’ drugs that are normally used for short-term (acute) pain and pain at the end of life. Unfortunately, these drugs are also prescribed for long-term (chronic) pain with little evidence that they are helpful.

Couple with corporate greed, this has led to widespread misuse and a sharp rise in overdose deaths, particularly in the United States. In 2018, there were more than 46,000 fentanyl related deaths, representing over two thirds of all US opioid related deaths that year.


Some studies have suggested that increased access to cannabis stores — legally authorized to sell medical and recreational cannabis — may help to reduce opioid related deaths.

Making a Case for Cannabis

To explore this further, researchers examined relationships between medical and recreational cannabis stores (referred to as dispensaries) and opioid related deaths from 2014 to 2018.

Their findings are based on data for 812 counties within the 23 US states that allowed legal cannabis dispensaries to operate by the end of 2017.

Information on state level cannabis legislation was combined with county level data on licensed dispensaries and opioid related mortality rates.

After controlling for population characteristics and other potentially influential factors, the researchers found that counties with a higher number of active cannabis dispensaries were associated with reduced opioid related mortality rates.

According to this estimate, an increase from one to two dispensaries in a county was associated with an estimated 17% reduction in all opioid related mortality rates.


This association held for both medical and recreational dispensaries and appeared particularly strong for deaths associated with synthetic opioids other than methadone, with an estimated 21% reduction in mortality rates associated with an increase from one to two dispensaries.

An increase from two to three dispensaries was associated with a further 8.5% reduction in all opioid related mortality rates.

This study is the first to examine the association between active cannabis dispensary operations and opioid related mortality rates at the more fine grained county level.

Their findings suggest “a potential association between increased prevalence of medical and recreational cannabis dispensaries and reduced opioid related mortality rates.”

However, these results are mostly observational and are in no way conclusive. Further experimental studies including individual level data of those with use of prescription opioids and illicit opioids “would inform a more nuanced understanding of the substitution between opioids and cannabis,” they conclude.